Zosano Pharma
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company that develops proprietary microneedle-based transdermal drug delivery systems, primarily targeting acute migraine patients. As of its February 2022 capital raise, the company remained pre-commercialization, with website activity subsequently ceased.
- Company typePublic
- Founded2006
- HeadquartersFremont, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Zosano Pharma does
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Fremont, California, that has developed a proprietary microneedle-based transdermal drug delivery platform. The company's core technology enables painless, minimally invasive administration of therapeutics through the skin, with a value proposition centered on improved patient compliance and reduced cold chain requirements. In April 2021, Zosano extended this platform by launching a temperature-stable vaccine delivery patch designed to eliminate cold chain storage requirements for vaccine distribution. The company's identified primary therapeutic focus is acute migraine treatment, positioning it in the horizontal use-case segment of migraine patients.
As a publicly traded company on NASDAQ under ticker ZSAN, Zosano has historically funded operations through equity financings rather than product revenue. Across at least 14 disclosed funding rounds between 2007 and 2022, the company raised cumulative proceeds exceeding $250 million, with the most recent being a $15.4 million public offering of common stock and warrants in February 2022 priced at $0.30 per unit. Proceeds from the February 2022 raise were explicitly designated for pre-commercialization activities and general corporate purposes, confirming the company had not yet generated product revenue at the time of its last capital raise. The company operates in the microneedle drug delivery market alongside larger competitors including 3M and Becton Dickinson.
A material concern is signaled by the fact that the company's website domain (zosanopharma.com) has expired and is currently parked with GoDaddy as of the data capture, indicating probable operational cessation or material disruption following the February 2022 financing. Leadership disclosure is limited to two named executives: Chris Kruegar (Chief Business Officer) and Peter Daddona (Executive Vice President and Chief Scientific Officer). Given the expired domain and absence of post-2022 operational signals, the company's current operating status is uncertain.
Zosano Pharma firmographics
Firmographics- Name
- Zosano Pharma
- Legal name
- Zosano Pharma Corporation
- Website
- https://zosanopharma.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Zosano Pharma Corporation is a clinical-stage biopharmaceutical company that develops proprietary microneedle-based transdermal drug delivery systems, primarily targeting acute migraine patients. As of its February 2022 capital raise, the company remained pre-commercialization, with website activity subsequently ceased.
- Ownership category
- akta.pro rank
Zosano Pharma industry classification
Industry- Product category
- Transdermal drug delivery systems
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF)
- akta.pro secondary industries
- Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Zosano Pharma is headquartered
LocationHeadquarters
- HQ city
- Fremont
- HQ country
- United States
- HQ region
- North America
Markets served
Zosano Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Zosano Pharma product offering
Product offeringCore offering
Zosano Pharma develops a proprietary microneedle transdermal drug delivery technology platform for pharmaceutical and vaccine administration. The company is pre-commercialization, working on a temperature-stable vaccine delivery patch and broader drug delivery applications targeting pain management and acute migraine relief.
Product overview
Zosano Pharma is a pharmaceutical company specializing in microneedle-based drug delivery systems. The company's primary product offering is a temperature-stable vaccine delivery patch introduced in April 2021. The company operates in the broader microneedle drug delivery systems market, competing with established players like 3M Company, Becton Dickinson and Company, and Nanopass Technologies. Zosano Pharma's microneedle technology enables painless drug administration through the skin.
Differentiator
Problem solved
Functional benefit
Products and services
- Temperature-Stable Vaccine Delivery Patch A microneedle-based patch for vaccine administration that is temperature-stable, designed to eliminate the need for cold chain storage and provide painless, self-applicable delivery for healthcare providers and patients.
- Microneedle Transdermal Drug Delivery Platform A proprietary transdermal microneedle delivery platform for pharmaceutical compounds, intended to enable needle-free, painless drug administration with potential applications in pain management and acute migraine relief.
Companies that use Zosano Pharma
Customer profileSegments1 record
Ideal customer profiles1 record
Zosano Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Zosano Pharma partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights3 records
Zosano Pharma competitors and assessment
Company assessmentDirect peers
- Becton, Dickinson and Company (BD): One of the named direct competitors of Zosano in the microneedle drug delivery market. BD has a much larger medical device and drug delivery franchise, making it the most relevant scaled direct peer for Zosano's microneedle platform.
- 3M Company: Named as a direct competitor in the global microneedle drug delivery market. 3M's drug delivery and life sciences businesses are directly comparable to Zosano's microneedle-based delivery approach.
- Nanopass Technologies: Direct competitor explicitly cited in Zosano's product overview. Nanopass develops microneedle-based delivery systems for vaccines and therapeutics and is the closest pure-play microneedle peer.
Emerging players
- Vaxxas: Develops high-density microarray patches for vaccine and therapeutic delivery — closely aligned with Zosano's temperature-stable vaccine patch concept and the broader needle-free delivery thesis.
- Corium (adhesive-based transdermal and microneedle delivery): Specializes in transdermal drug delivery, including microneedle-based products. Operates in the same transdermal/microneedle delivery category as Zosano, though with a broader portfolio and more advanced commercialization.
- Tonix Pharmaceuticals: Specialty pharmaceutical company developing CNS and pain therapies, including migraine-related programs. Comparable to Zosano's migraine / neurology focus area within specialty pharma.
- Theratechnologies: Specialty biopharmaceutical company developing therapeutics in endocrinology and HIV, with a smaller-scale, pre-commercial-to-commercial profile comparable to Zosano's specialty pharma stage.
Broad incumbents
- Noven Pharmaceuticals: A long-established transdermal drug delivery company (now part of Hisamitsu) specializing in patch-based pharmaceutical delivery. A comparable, larger incumbent in the broader transdermal delivery space Zosano targets.
- LTS Lohmann Therapie-Systeme: One of the world's largest transdermal patch and oral thin-film manufacturers. Comparable as a scaled, established player in transdermal drug delivery technology that Zosano is also addressing.
- BioDelivery Sciences International (BDSI, now part of Collegium Pharmaceutical): Specialty pharmaceutical company focused on pain management and neurology, an area that overlaps with Zosano's acute migraine use case. Comparable as a specialty pharma commercializing differentiated pain/neurology therapies.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat1 record
Key risks5 records
Key highlights4 records
Customer concentration
Zosano Pharma social profiles
Digital presenceZosano Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Zosano Pharma leadership team
Management profileNumber of profiles
Profiles2 records
Zosano Pharma funding detail
Funding detailFunding overview
Funding rounds14 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Zosano Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Zosano Pharma
What does Zosano Pharma do?
Zosano Pharma develops a proprietary microneedle transdermal drug delivery technology platform for pharmaceutical and vaccine administration. The company is pre-commercialization, working on a temperature-stable vaccine delivery patch and broader drug delivery applications targeting pain management and acute migraine relief.
Is Zosano Pharma a public or private company?
Zosano Pharma is a public company. It is classified as public and is currently operating.
When was Zosano Pharma founded?
Zosano Pharma was founded in 2006. It employs 11 to 50 people.
Where is Zosano Pharma based?
Zosano Pharma is headquartered in Fremont, United States, in the North America region.
Who are Zosano Pharma's main competitors?
Direct peers on record are Becton, Dickinson and Company (BD), 3M Company and Nanopass Technologies. Emerging players are Vaxxas, Corium (adhesive-based transdermal and microneedle delivery), Tonix Pharmaceuticals and Theratechnologies. Broad incumbents are Noven Pharmaceuticals, LTS Lohmann Therapie-Systeme and BioDelivery Sciences International (BDSI, now part of Collegium Pharmaceutical).
Does Zosano Pharma have an API?
No public API is recorded for Zosano Pharma.
What industry is Zosano Pharma in?
Zosano Pharma's product category is Transdermal drug delivery systems. Its primary akta.pro industry code is HLAAAEAF, Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral), with a secondary code of HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.